



# IPO INSIGHTS



## Akums Drugs and Pharmaceuticals Limited

**Issue Dates - Opens: 30-07-2024 | Closes: 01-08-2024**

<b>IPO Note</b>	<ol style="list-style-type: none"> <li><b>Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.</b></li> <li><b>The Company also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients.</b></li> </ol>
<b>Rating</b>	<b>★★ (Average)</b>

## IPO SNAPSHOT

<b>Issue Size</b>	<b>₹1856.74 Crores</b>
<b>Issue Type</b>	<b>Book Built Issue IPO</b>
<b>Fresh Issue</b>	<b>₹680 Crores</b>
<b>Offer for Sale</b>	<b>₹1176.74 Crores</b>
<b>Face Value Per Share</b>	<b>₹2</b>
<b>Price Band Per Share</b>	<b>₹646 to ₹679</b>
<b>Minimum Lot Size</b>	<b>22 shares</b>
<b>Listing On</b>	<b>BSE, NSE</b>
<b>Registrar to the Issue</b>	<b>Link Intime India Private Ltd</b>

# IPO SNAPSHOT – Akums Drugs and Pharmaceuticals Limited

<b>About the Company</b>	<ul style="list-style-type: none"> <li>▪ Incorporated in 2004</li> <li>▪ The Company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&amp;D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services.</li> <li>▪ The Company own the intellectual property for the manufacturing processes of several of their formulations, and their core business is focused on providing end-to-end product development and manufacturing solutions to our clients.</li> <li>▪ They produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.</li> <li>▪ Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.</li> <li>▪ The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025.</li> </ul>																														
<b>Competitive Strengths</b>	<ul style="list-style-type: none"> <li>▪ Largest CDMO serving the Indian pharmaceutical industry</li> <li>▪ Diverse client base with longstanding CDMO relationships</li> <li>▪ Large and rapidly growing R&amp;D capabilities across our product portfolio</li> <li>▪ Strategic presence across the pharmaceutical value chain</li> <li>▪ Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused private equity investor</li> </ul>																														
<b>Financials (₹ in Crores)</b>	<table border="1"> <thead> <tr> <th>Particulars</th> <th>31-3-2022</th> <th>31-3-2023</th> <th>31-03-2024</th> <th>Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue</td> <td>3671.89</td> <td>3654.82</td> <td>4178.18</td> <td>14%</td> </tr> <tr> <td>EBITDA</td> <td>-91.72</td> <td>337.95</td> <td>122.98</td> <td>-64%</td> </tr> <tr> <td>EBITDA Margin</td> <td>-2.5%</td> <td>9.2%</td> <td>2.9%</td> <td></td> </tr> <tr> <td>PAT</td> <td>-250.87</td> <td>97.82</td> <td>0.79</td> <td>-99%</td> </tr> <tr> <td>PAT Margin</td> <td>-2.5%</td> <td>9.2%</td> <td>0.02%</td> <td></td> </tr> </tbody> </table>	Particulars	31-3-2022	31-3-2023	31-03-2024	Y-o-Y	Revenue	3671.89	3654.82	4178.18	14%	EBITDA	-91.72	337.95	122.98	-64%	EBITDA Margin	-2.5%	9.2%	2.9%		PAT	-250.87	97.82	0.79	-99%	PAT Margin	-2.5%	9.2%	0.02%	
Particulars	31-3-2022	31-3-2023	31-03-2024	Y-o-Y																											
Revenue	3671.89	3654.82	4178.18	14%																											
EBITDA	-91.72	337.95	122.98	-64%																											
EBITDA Margin	-2.5%	9.2%	2.9%																												
PAT	-250.87	97.82	0.79	-99%																											
PAT Margin	-2.5%	9.2%	0.02%																												
<b>Valuation</b>	<ul style="list-style-type: none"> <li>▪ Not Applicable : The PE ratio is not applicable due to exceptionally low profits</li> </ul>																														
<b>Peers</b>	<table border="1"> <thead> <tr> <th>Company Name</th> <th>P/E ratio</th> </tr> </thead> <tbody> <tr> <td>Divi's Laboratories Limited</td> <td>79.49</td> </tr> <tr> <td>Suven Pharmaceuticals Limited</td> <td>78.68</td> </tr> <tr> <td>Gland Pharmaceuticals Limited</td> <td>42.99</td> </tr> <tr> <td>Torrent Pharmaceuticals Limited</td> <td>65.28</td> </tr> <tr> <td>Alkem Laboratories Limited</td> <td>28.56</td> </tr> <tr> <td>Eris Lifesciences Limited</td> <td>37.25</td> </tr> <tr> <td>JB Chemicals Limited</td> <td>52.85</td> </tr> <tr> <td>Mankind Pharmaceuticals Limited</td> <td>43.06</td> </tr> <tr> <td>Innova Captab Limited</td> <td>32.67</td> </tr> </tbody> </table> <p>Note : P/E ratio is calculated as closing share price as on 26th July,2024.</p>	Company Name	P/E ratio	Divi's Laboratories Limited	79.49	Suven Pharmaceuticals Limited	78.68	Gland Pharmaceuticals Limited	42.99	Torrent Pharmaceuticals Limited	65.28	Alkem Laboratories Limited	28.56	Eris Lifesciences Limited	37.25	JB Chemicals Limited	52.85	Mankind Pharmaceuticals Limited	43.06	Innova Captab Limited	32.67										
Company Name	P/E ratio																														
Divi's Laboratories Limited	79.49																														
Suven Pharmaceuticals Limited	78.68																														
Gland Pharmaceuticals Limited	42.99																														
Torrent Pharmaceuticals Limited	65.28																														
Alkem Laboratories Limited	28.56																														
Eris Lifesciences Limited	37.25																														
JB Chemicals Limited	52.85																														
Mankind Pharmaceuticals Limited	43.06																														
Innova Captab Limited	32.67																														
<b>Promoters</b>	<ul style="list-style-type: none"> <li>▪ Sanjeev Jain</li> <li>▪ Sandeep Jain</li> <li>▪ Akums Master Trust</li> </ul>																														
<b>Objects of the issue</b>	<ul style="list-style-type: none"> <li>▪ Repayment/ prepayment of indebtedness of the company and it subsidiaries.</li> <li>▪ Funding incremental working capital requirements of the company.</li> <li>▪ Pursuing inorganic growth initiatives through acquisitions.</li> <li>▪ General Corporate Purposes</li> </ul>																														

## DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

